

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: William J. Curatolo, et al.

SERIAL NO.: 09/770,562

: Examiner: B. Fubara

: Art Unit: 1618

FILED: January 26, 2001

:

FOR: Solid Pharmaceutical Dispersions
With Enhanced Bioavailability

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RESPONSE TO OFFICE ACTION

This is in response to the Office Action (an election of species requirement) mailed on August 31, 2007 in the above-identified application, the term for response having been extended four (4) months to January 31, 2008 by including the appropriate fee and petition herewith.

Remarks

In response to the elect a specific drug species, applicants elect ziprasidone. Ziprasidone was specifically named by the Examiner at page 3 of the office action, third line. The Examiner is requested to consider ziprasidone in all of its forms, including the free base an/or any of its pharmaceutically acceptable salts such as the hydrochloride (see Applicants' specification at page 10, lines 1-3).

Claims 1, 4, 15, 17, 22-23, 26, 36-37, 49-51, 53-56 are readable on the elected species.

A Notice of Allowance is courteously solicited. The Commissioner is hereby authorized to charge any additional fees which may be required, or to credit any overpayment, to Deposit Account No. 16-1445. Two copies of this sheet are enclosed.

Date: JANUARY 31, 2008

Respectfully submitted,


James T. Jones

Attorney for Applicant
Reg. No. 30,561

Pfizer Inc
Eastern Point Road
Groton, CT 06340
(860) 441-4903